A Phase 3 interventional study of Imatinib and Nilotinib in Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 110 sites in 29 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 5 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 11th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Thomas Ernst, Prof. Dr. med. · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Spain
Ages 18+
Novartis Pharmaceuticals · Sites in France
Ages 18–99
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 5 · Phase 4 2
First in 2014; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 405 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 100 across the 21 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 9th largest by enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2021, is one of 19 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 68th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
2 of the studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03906292University of JenaFrontline Asciminib Combination in Chronic Phase CML | 2027-03 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD.
This study has three periods: 1. Treatment period for all randomized participants, 2. Optional Treatment-Free Remission (TFR) period only for participants meeting TFR eligibility criteria and 3. Treatment Re-Initiation (TRI) period only for participants who relapsed after TFR attempt.
This study is a phase III, multi-center, open-label, randomized study of oral asciminib 80 mg QD versus Investigator selected TKI (imatinib, nilotinib, dasatinib, or bosutinib) in adult patients with newly diagnosed Ph+ CML-CP. All comparator TKIs will be made available, unless not permitted by local regulations or local Health Authority or not approved for the treatment of CML in the country.
Approximately 402 patients will be randomized in a 1:1 ratio to asciminib and Investigator selected TKI to join the treatment period.
Randomization will be stratified based on the following two stratification factors:
Prior to randomization, the Investigator, in consultation with the patient, considering the current treatment paradigm and patient characteristics and comorbidities, will make a selection of preference for imatinib or 2G TKI (nilotinib or dasatinib or bosutinib) if the patient is randomized to the comparator arm. The stratified randomization based on these two stratification factors will help to achieve a balance across the treatment arms for the possible comorbidities and baseline characteristics of patients enrolled in the study.
To further ensure that the distribution of patients, between imatinib and 2G TKIs (nilotinib or dasatinib or bosutinib), in the Investigator selected TKI arm is reflective of the use of these agents in clinical practice, the enrollment into the strata of imatinib versus 2G TKI (nilotinib or dasatinib or bosutinib) based on the pre-randomization selection of TKI will be managed by Interactive Response Technology to be approximately 50% versus 50%.
Treatment arms: The study will have 2 treatment arms:
Apart from the treatment period described above, the present study comprises an optional Treatment-Free Remission (TFR) Period enrolling consenting participants of the treatment period (receiving asciminib or IS-TKI) who will discontinue their randomized treatment if they meet per protocol eligibility criteria. The optional TFR Period will last at least 2 years to assess the feasibility of TFR and TFR outcomes following discontinuation of their randomized treatment (asciminib or IS-TKI).
In addition, during the TFR Period, participants who will lose major molecular response (MMR) must re-initiate treatment and will enter into a Treatment Reinitiation (TRI) Period.
During the treatment period, no crossover of study treatment across arms and no change of study treatment within the Investigator selected TKI will be allowed. For specifically participants who must transition into the TRI Period, at the time of treatment re-initiation: a) participants who were previously treated with asciminib will resume asciminib at the same dose prior to entry into TFR. b) participants who were on IS-TKI may either continue with the same study treatment they were randomized to and at the same dose prior to entry into TFR or may switch to asciminib with a starting dose of 80 mg QD.
Duration of Study treatment: Patients on the study will continue to receive the assigned treatment until the End of Study, premature discontinuation due to treatment failure, disease progression or intolerance, due to Investigator or participant decision. or due to patient going to TFR Period and/or TRI Period.
Duration of study: The End of Study will occur 8 years from the last patient first treatment in the study. Patients who discontinue study treatment prematurely due to any reason, will be followed up for survival and progression (to AP/BC) until the End of Study.
Inclusion Criteria for treatment period:
Participants eligible for inclusion in this study must meet all of the following criteria:
Documented chronic phase CML will meet all the below criteria (Hochhaus et al 2020):
No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly.
Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not and not associated with risk factors for acute pancreatitis
- Participants must have the following laboratory values within normal limits or corrected to within normal limits with supplements prior to randomization:
*CrCl as calculated using Cockcroft-Gault formula
Exclusion Criteria for Treatment period:
Impaired cardiac function or cardiac repolarization abnormality including but not limited to any one of the following:
Other protocol-defined Inclusion/exclusion criteria will apply.
Inclusion Criteria for optional TFR period:
Participants meeting the following additional criteria are not eligible to enter the TRI Period:
Exclusion Criteria for optional TFR period:
Exclusion Criteria for Treatment Re-initiation (TRI) Period
Participants meeting the following additional criterion are not eligible to enter the TRI Period:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will take asciminib 80 mg QD under fasting conditions on ongoing basis; Patients will be randomized 1:1 asciminib versus Investigator selected TKIs
Drug: Asciminib
Patients will take on ongoing basis the Investigator selected TKIs that will include one of the below treatments: Imatinib 400 mg QD administered with food Nilotinib 300 mg BID administered under fasting conditions Dasatinib 100 mg QD administered with or without a meal Bosotunib 400 mg QD administered with food
Drug: Imatinib · Drug: Nilotinib · Drug: Bosutinib · Drug: Dasatinib
Comes in 100 mg and 400 mg tablets and taken orally
Also known as: STI571
Comes in 150 mg and 200 mg capsules and taken orally
Also known as: AMN107
Comes in 100 mg and 400 mg tablets and taken orally
Comes in 20 mg, 50 mg, 70 mg and 100 mg tablets and taken orally
Comes in 40 mg tablets and taken orally
Also known as: ABL001
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI
Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Time frame: At 48 weeks
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)
Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL1/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Time frame: At 48 weeks
Major Molecular Response at Week 96
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Time frame: at 96 weeks (96 weeks after last patient first dose)
Time to Discontinuation of Study Treatment Due to Adverse Events (TTDAE)
TTDAE is defined as the time from the date of first dose of study treatment to the date of discontinuation of study treatment due to Adverse Event (AE). For patients ongoing without study treatment discontinuation, on or prior to the analysis cut-off date, the time will be censored at the at the analysis cut-off date.
Time frame: 96 weeks after last patient first dose
Major Molecular Response at Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Time frame: Planned total follow-up duration of 5 years
Major Molecular Response by Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Time frame: Planned total follow-up duration of 5 years
MR4.0 at Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).
Time frame: Planned total follow-up duration of 5 years
MR4.5 at All Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).
Time frame: Planned total follow-up duration of 5 years
MR4.0 by Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).
Time frame: Planned total follow-up duration of 5 years
MR4.5 by All Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).
Time frame: Planned total follow-up duration of 5 years
Complete Hematological Response (CHR) at All Scheduled Data Collection Time Points
Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver
Time frame: Planned total follow-up duration of 5 years
Complete Hematological Response (CHR) by All Scheduled Data Collection Time Points
Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver
Time frame: Planned total follow-up duration of 5 years
Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96
The CCyR response status was to be based on bone marrow assessment. Bone marrow examination for cytogenetic assessment was to be performed locally by the Investigator at baseline for all participants. Thereafter, during the course of the study, cytogenetic assessment was not mandatory and only performed if clinically indicated.
Time frame: By week 48 and by week 96 (48 weeks and 96 weeks after last patient first dose); data collection/analysis is ongoing for the 96 week time point, and the data will be reported later
Duration of MMR
Duration of MMR is defined as the time between the date of the first documented achievement of MMR and the earliest date of loss of MMR, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death
Time frame: Planned total follow-up duration of 5 years
Duration of MR4.0
Duration of MR4.0 is defined as the time between the date of the first documented achievement of MR4.0 and the earliest date of loss of MR4.0, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death
Time frame: Planned total follow-up duration of 5 years
Duration of MR4.5
Duration of MR4.5 is defined as the time between the date of the first documented achievement of MR4.5 and the earliest date of loss of MR4.5, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death
Time frame: Planned total follow-up duration of 5 years
Time to First MMR
Time to first MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MMR.
Time frame: Planned total follow-up duration of 5 years
Time to First MR4.0
Time to first MR4.0 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.0. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.0.
Time frame: Planned total follow-up duration of 5 years
Time to First MR4.5
Time to first MR4.5 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.5. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.5.
Time frame: Planned total follow-up duration of 5 years
BCR-ABL1≤1% at Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.
Time frame: Planned total follow-up duration of 5 years
BCR-ABL1≤1% by Scheduled Data Collection Time Points
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.
Time frame: Planned total follow-up duration of 5 years
Time to Treatment Failure (TTF)
TTF is defined as the time from date of randomization to the first/earliest documented date of any of the following events: treatment failure as per ELN, Confirmed loss of MMR while on study treatment, discontinuation from study treatment due to any reason For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the last study assessment date while on treatment, or the EOT (whichever comes first) .
Time frame: Planned total follow-up duration of 5 years
Failure Free Survival (FFS)
FFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure per ELN, confirmed loss of MMR, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.
Time frame: Planned total follow-up duration of 5 years
Event Free Survival (EFS)
EFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure as per ELN, confirmed loss of MMR ,discontinuation of study treatment due to AE, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.
Time frame: Planned total follow-up duration of 5 years
Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization to the earliest occurrence of progression to AP/BC or death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.
Time frame: Planned total follow-up duration of 5 years
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last contact before the cut-off date.
Time frame: Planned total follow-up duration of 5 years
Trough Plasma Concentrations.
Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.
Time frame: Week 48
Pharmacokinetics (PK) of Asciminib: Cmax
Cmax is the maximum serum concentration of asciminib during a dosing interval (mass x volume-1).
Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
PK of Asciminib: Tmax
Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)
Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
PK of Asciminib: AUCtau and AUClast
AUCtau is the area under the plasma concentration-time curve over the dosing interval. AUClast is the area under the plasma concentration-time curve from time zero (time of dose administration) to time of last measurable concentration (mass x time x volume-1)
Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
PK of Asciminib: CL/F
CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).
Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
Change From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96
The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses the quality of life of cancer patients. It consists of functioning scales, symptom scales, and the global health status quality of life (QoL) scale. A high score for functional and QoL items/scales from the QLQ-30 represents better function and QOL. A high score in symptoms items from QLQ-30 represents worse symptoms.
Time frame: Baseline, week 48 and week 96
Change From Baseline in EORTC QLQ-CML24 Scales at Week 48 and Week 96
The QLQ-CML24 consists of multi-scale items: symptom burden, impact on worry/mood, impact on daily life, body image problems, satisfaction with care and information and satisfaction with social life. A higher score on most of the item scales in QLQ-CML24 reflects a larger impairment in the corresponding domain, with the exception of the satisfaction with care and information, and problems and satisfaction with social life, where a higher score reflects a higher level of satisfaction.
Time frame: Baseline, week 48 and week 96.
All trial participants randomized in a 1:1 ratio between asciminib and investigator selected TKI (imatinib 400 mg QD, nilotinib 300 mg BD, dasatinib 100 mg QD or bosutinib 400 mg QD).
| Milestone | Asciminib (Imatinib Stratum) | Asciminib (2nd Generation TKI Stratum) | Investigator Selected TKI (Imatinib Stratum) | Investigator Selected TKI (2nd Generation TKI Stratum |
|---|---|---|---|---|
| Started | 101 | 100 | 102 | 102 |
| Participants not treated | 1 | 0 | 2 | 1 |
| Treated | 100 | 100 | 100 | 101 |
| Completed | 85 | 88 | 63 | 77 |
| Not completed | 16 | 12 | 39 | 25 |
| Withdrew: Unsatisfactory therapeutic effect | 6 | 6 | 21 | 10 |
| Withdrew: Adverse event | 6 | 5 | 11 | 10 |
| Withdrew: Progressive disease | 2 | 0 | 3 | 1 |
| Withdrew: Protocol deviation | 1 | 0 | 1 | 1 |
| Withdrew: Subject decision | 0 | 1 | 1 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Participants not treated | 1 | 0 | 2 | 1 |
Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
| Participants | Asciminib (All Asciminib ) | Investigator Selected TKI (All Comparators) |
|---|---|---|
| Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI | 136 | 100 |
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Results for this outcome have not been posted.
TTDAE is defined as the time from the date of first dose of study treatment to the date of discontinuation of study treatment due to Adverse Event (AE). For patients ongoing without study treatment discontinuation, on or prior to the analysis cut-off date, the time will be censored at the at the analysis cut-off date.
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).
Results for this outcome have not been posted.
Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver
Results for this outcome have not been posted.
Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver
Results for this outcome have not been posted.
The CCyR response status was to be based on bone marrow assessment. Bone marrow examination for cytogenetic assessment was to be performed locally by the Investigator at baseline for all participants. Thereafter, during the course of the study, cytogenetic assessment was not mandatory and only performed if clinically indicated.
| Participants | Asciminib (All Asciminib ) | Investigator Selected TKI (All Comparators) |
|---|---|---|
| Complete cytogenetic response (CCyR) | 1 | 0 |
| Partial cytogenetic response (PCyR) | 1 | 0 |
| Minor cytogenetic response (mCyR) | 0 | 0 |
| Minimal cytogenetic response | 0 | 0 |
| No cytogenetic response | 0 | 0 |
Duration of MMR is defined as the time between the date of the first documented achievement of MMR and the earliest date of loss of MMR, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death
Results for this outcome have not been posted.
Duration of MR4.0 is defined as the time between the date of the first documented achievement of MR4.0 and the earliest date of loss of MR4.0, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death
Results for this outcome have not been posted.
Duration of MR4.5 is defined as the time between the date of the first documented achievement of MR4.5 and the earliest date of loss of MR4.5, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death
Results for this outcome have not been posted.
Time to first MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MMR.
Results for this outcome have not been posted.
Time to first MR4.0 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.0. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.0.
Results for this outcome have not been posted.
Time to first MR4.5 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.5. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.5.
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.
Results for this outcome have not been posted.
Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.
Results for this outcome have not been posted.
TTF is defined as the time from date of randomization to the first/earliest documented date of any of the following events: treatment failure as per ELN, Confirmed loss of MMR while on study treatment, discontinuation from study treatment due to any reason For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the last study assessment date while on treatment, or the EOT (whichever comes first) .
Results for this outcome have not been posted.
FFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure per ELN, confirmed loss of MMR, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.
Results for this outcome have not been posted.
EFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure as per ELN, confirmed loss of MMR ,discontinuation of study treatment due to AE, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.
Results for this outcome have not been posted.
PFS is defined as the time from the date of randomization to the earliest occurrence of progression to AP/BC or death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.
Results for this outcome have not been posted.
OS is defined as the time from the date of randomization to the date of death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last contact before the cut-off date.
Results for this outcome have not been posted.
Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.
| ng/mL | Asciminib (All Asciminib ) |
|---|---|
| Trough Plasma Concentrations. | 161 (11.9 to 1010) |
Cmax is the maximum serum concentration of asciminib during a dosing interval (mass x volume-1).
| ng/mL | Asciminib (All Asciminib) |
|---|---|
| Pharmacokinetics (PK) of Asciminib: Cmax | 1470 ± 38.2 |
Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)
| Hour (hr) | Asciminib (All Asciminib) |
|---|---|
| PK of Asciminib: Tmax | 2.00 (0.883 to 3.18) |
AUCtau is the area under the plasma concentration-time curve over the dosing interval. AUClast is the area under the plasma concentration-time curve from time zero (time of dose administration) to time of last measurable concentration (mass x time x volume-1)
| ng*hr/mL | Asciminib (All Asciminib) |
|---|---|
| AUClast | 8590 ± 42.2 |
| AUCtau | NA ± NA |
CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).
| ng*hr/mL | Asciminib (All Asciminib) |
|---|---|
| PK of Asciminib: CL/F | NA ± NA |
The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses the quality of life of cancer patients. It consists of functioning scales, symptom scales, and the global health status quality of life (QoL) scale. A high score for functional and QoL items/scales from the QLQ-30 represents better function and QOL. A high score in symptoms items from QLQ-30 represents worse symptoms.
| Participants | Asciminib (All Asciminib ) | Investigator Selected TKI (All Comparators) |
|---|---|---|
| Global health status/QoL — Very much better | 10 | 6 |
| Global health status/QoL — Moderately better | 18 | 7 |
| Global health status/QoL — A little better | 6 | 6 |
| Global health status/QoL — Unchanged | 28 | 26 |
| Global health status/QoL — A little worse | 5 | 6 |
| Global health status/QoL — Moderately worse | 10 | 12 |
| Global health status/QoL — Very much worse | 2 | 7 |
| Physical functioning — Very much better | 3 | 3 |
| Physical functioning — Moderately better | 10 | 12 |
| Physical functioning — A little better | 16 | 12 |
| Physical functioning — Unchanged | 32 | 26 |
| Physical functioning — A little worse | 7 | 8 |
| Physical functioning — Moderately worse | 10 | 6 |
| Physical functioning — Very much worse | 1 | 3 |
| Role functioning — Very much better | 5 | 7 |
| Role functioning — Moderately better | 10 | 7 |
| Role functioning — A little better | 0 | 0 |
| Role functioning — Unchanged | 54 | 41 |
| Role functioning — A little worse | 0 | 0 |
| Role functioning — Moderately worse | 4 | 7 |
| Role functioning — Very much worse | 6 | 8 |
| Emotional functioning — Very much better | 9 | 10 |
| Emotional functioning — Moderately better | 7 | 6 |
| Emotional functioning — A little better | 14 | 9 |
| Emotional functioning — Unchanged | 31 | 24 |
| Emotional functioning — A little worse | 7 | 10 |
| Emotional functioning — Moderately worse | 5 | 5 |
| Emotional functioning — Very much worse | 6 | 6 |
| Cognitive functioning — Very much better | 3 | 1 |
| Cognitive functioning — Moderately better | 13 | 8 |
| Cognitive functioning — A little better | 0 | 0 |
| Cognitive functioning — Unchanged | 44 | 36 |
| Cognitive functioning — A little worse | 0 | 0 |
| Cognitive functioning — Moderately worse | 16 | 19 |
| Cognitive functioning — Very much worse | 3 | 6 |
| Social functioning — Very much better | 7 | 6 |
| Social functioning — Moderately better | 14 | 6 |
| Social functioning — A little better | 0 | 0 |
| Social functioning — Unchanged | 51 | 40 |
| Social functioning — A little worse | 0 | 0 |
| Social functioning — Moderately worse | 4 | 7 |
| Social functioning — Very much worse | 3 | 11 |
| Fatigue — Very much better | 19 | 11 |
| Fatigue — Moderately better | 16 | 16 |
| Fatigue — A little better | 0 | 0 |
| Fatigue — Unchanged | 26 | 16 |
| Fatigue — A little worse | 0 | 0 |
| Fatigue — Moderately worse | 11 | 11 |
| Fatigue — Very much worse | 7 | 16 |
| Nausea and vomiting — Very much better | 1 | 1 |
| Nausea and vomiting — Moderately better | 7 | 5 |
| Nausea and vomiting — A little better | 0 | 0 |
| Nausea and vomiting — Unchanged | 67 | 48 |
| Nausea and vomiting — A little worse | 0 | 0 |
| Nausea and vomiting — Moderately worse | 3 | 11 |
| Nausea and vomiting — Very much worse | 1 | 5 |
| Pain — Very much better | 9 | 3 |
| Pain — Moderately better | 17 | 11 |
| Pain — A little better | 0 | 0 |
| Pain — Unchanged | 45 | 37 |
| Pain — A little worse | 0 | 0 |
| Pain — Moderately worse | 5 | 10 |
| Pain — Very much worse | 3 | 9 |
| Dyspnoea — Very much better | 11 | 9 |
| Dyspnoea — Moderately better | 0 | 0 |
| Dyspnoea — A little better | 0 | 0 |
| Dyspnoea — Unchanged | 59 | 49 |
| Dyspnoea — A little worse | 0 | 0 |
| Dyspnoea — Moderately worse | 0 | 0 |
| Dyspnoea — Very much worse | 9 | 12 |
| Insomnia — Very much better | 14 | 10 |
| Insomnia — Moderately better | 0 | 0 |
| Insomnia — A little better | 0 | 0 |
| Insomnia — Unchanged | 50 | 43 |
| Insomnia — A little worse | 0 | 0 |
| Insomnia — Moderately worse | 0 | 0 |
| Insomnia — Very much worse | 15 | 17 |
| Appetite loss — Very much better | 16 | 11 |
| Appetite loss — Moderately better | 0 | 0 |
| Appetite loss — A little better | 0 | 0 |
| Appetite loss — Unchanged | 59 | 51 |
| Appetite loss — A little worse | 0 | 0 |
| Appetite loss — Moderately worse | 0 | 0 |
| Appetite loss — Very much worse | 4 | 8 |
| Constipation — Very much better | 8 | 14 |
| Constipation — Moderately better | 0 | 0 |
| Constipation — A little better | 0 | 0 |
| Constipation — Unchanged | 58 | 40 |
| Constipation — A little worse | 0 | 0 |
| Constipation — Moderately worse | 0 | 0 |
| Constipation — Very much worse | 13 | 16 |
| Diarrhoea — Very much better | 11 | 8 |
| Diarrhoea — Moderately better | 0 | 0 |
| Diarrhoea — A little better | 0 | 0 |
| Diarrhoea — Unchanged | 61 | 43 |
| Diarrhoea — A little worse | 0 | 0 |
| Diarrhoea — Moderately worse | 0 | 0 |
| Diarrhoea — Very much worse | 7 | 19 |
| Financial difficulties — Very much better | 12 | 14 |
| Financial difficulties — Moderately better | 0 | 0 |
| Financial difficulties — A little better | 0 | 0 |
| Financial difficulties — Unchanged | 63 | 49 |
| Financial difficulties — A little worse | 0 | 0 |
| Financial difficulties — Moderately worse | 0 | 0 |
| Financial difficulties — Very much worse | 4 | 7 |
The QLQ-CML24 consists of multi-scale items: symptom burden, impact on worry/mood, impact on daily life, body image problems, satisfaction with care and information and satisfaction with social life. A higher score on most of the item scales in QLQ-CML24 reflects a larger impairment in the corresponding domain, with the exception of the satisfaction with care and information, and problems and satisfaction with social life, where a higher score reflects a higher level of satisfaction.
| Participants | Asciminib (All Asciminib) | Investigator Selected TKI (All Comparators) |
|---|---|---|
| Symptom Burden — Very much better | 0 | 2 |
| Symptom Burden — Moderately better | 12 | 4 |
| Symptom Burden — A little better | 18 | 5 |
| Symptom Burden — Unchanged | 27 | 22 |
| Symptom Burden — A little worse | 7 | 16 |
| Symptom Burden — Moderately worse | 6 | 12 |
| Symptom Burden — Very much worse | 7 | 5 |
| Impact on Worry/Mood — Very much better | 11 | 7 |
| Impact on Worry/Mood — Moderately better | 7 | 9 |
| Impact on Worry/Mood — A little better | 20 | 6 |
| Impact on Worry/Mood — Unchanged | 17 | 18 |
| Impact on Worry/Mood — A little worse | 16 | 11 |
| Impact on Worry/Mood — Moderately worse | 2 | 4 |
| Impact on Worry/Mood — Very much worse | 4 | 11 |
| Impact on Daily Life — Very much better | 21 | 17 |
| Impact on Daily Life — Moderately better | 26 | 10 |
| Impact on Daily Life — A little better | 0 | 0 |
| Impact on Daily Life — Unchanged | 19 | 23 |
| Impact on Daily Life — A little worse | 0 | 0 |
| Impact on Daily Life — Moderately worse | 6 | 5 |
| Impact on Daily Life — Very much worse | 5 | 11 |
| Body Image Problems — Very much better | 18 | 10 |
| Body Image Problems — Moderately better | 0 | 0 |
| Body Image Problems — A little better | 0 | 0 |
| Body Image Problems — Unchanged | 48 | 41 |
| Body Image Problems — A little worse | 0 | 0 |
| Body Image Problems — Moderately worse | 0 | 0 |
| Body Image Problems — Very much worse | 11 | 15 |
| Satisfaction with Care and Information — Very much better | 8 | 13 |
| Satisfaction with Care and Information — Moderately better | 5 | 4 |
| Satisfaction with Care and Information — A little better | 0 | 0 |
| Satisfaction with Care and Information — Unchanged | 30 | 31 |
| Satisfaction with Care and Information — A little worse | 0 | 0 |
| Satisfaction with Care and Information — Moderately worse | 18 | 7 |
| Satisfaction with Care and Information — Very much worse | 16 | 11 |
| Satisfaction with Social Life — Very much better | 15 | 14 |
| Satisfaction with Social Life — Moderately better | 0 | 0 |
| Satisfaction with Social Life — A little better | 0 | 0 |
| Satisfaction with Social Life — Unchanged | 40 | 37 |
| Satisfaction with Social Life — A little worse | 0 | 0 |
| Satisfaction with Social Life — Moderately worse | 0 | 0 |
| Satisfaction with Social Life — Very much worse | 22 | 15 |
Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL1/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).
| Participants | Asciminib (Imatinib Stratum) | Investigator Selected TKI (Imatinib Stratum) |
|---|---|---|
| Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum) | 70 | 41 |
Collected over Adverse events (AEs) are collected from first dose of study treatment until end of study treatment plus 30 days post treatment. AEs reported in this record are from first dose of study treatment until data cut-off on 28-Nov-2023 (approx. 2 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asciminib (All Asciminib) | 0/200 (0%) | 22/200 (11%) | 177/200 (88.5%) |
| Imatinib | 0/99 (0%) | 12/99 (12.1%) | 89/99 (89.9%) |
| 2nd Generation TKI | 0/102 (0%) | 20/102 (19.6%) | 100/102 (98%) |
| All Comparators | 0/201 (0%) | 32/201 (15.9%) | 189/201 (94%) |
| Event | Asciminib (All Asciminib) | Imatinib | 2nd Generation TKI | All Comparators |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/200 | 1/99 | 3/102 | 4/201 |
| COVID-19Infections and infestations | 0/200 | 0/99 | 2/102 | 2/201 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/200 | 0/99 | 2/102 | 2/201 |
| Atrial fibrillationCardiac disorders | 0/200 | 1/99 | 0/102 | 1/201 |
| Abdominal pain upperGastrointestinal disorders | 0/200 | 1/99 | 0/102 | 1/201 |
| MelaenaGastrointestinal disorders | 0/200 | 1/99 | 0/102 | 1/201 |
| PancreatitisGastrointestinal disorders | 1/200 | 1/99 | 0/102 | 1/201 |
| Pancreatitis acuteGastrointestinal disorders | 1/200 | 1/99 | 0/102 | 1/201 |
| DiverticulitisInfections and infestations | 0/200 | 1/99 | 0/102 | 1/201 |
| Upper respiratory tract infectionInfections and infestations | 0/200 | 1/99 | 1/102 | 2/201 |
| Event | Asciminib (All Asciminib) | Imatinib | 2nd Generation TKI | All Comparators |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 23/200 | 26/99 | 23/102 | 49/201 |
| DiarrhoeaGastrointestinal disorders | 31/200 | 26/99 | 26/102 | 52/201 |
| HeadacheNervous system disorders | 26/200 | 8/99 | 22/102 | 30/201 |
| RashSkin and subcutaneous tissue disorders | 26/200 | 10/99 | 22/102 | 32/201 |
| NauseaGastrointestinal disorders | 18/200 | 21/99 | 18/102 | 39/201 |
| Neutrophil count decreasedInvestigations | 29/200 | 16/99 | 21/102 | 37/201 |
| COVID-19Infections and infestations | 35/200 | 18/99 | 20/102 | 38/201 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 4/200 | 19/99 | 5/102 | 24/201 |
| Alanine aminotransferase increasedInvestigations | 14/200 | 6/99 | 19/102 | 25/201 |
| FatigueGeneral disorders | 28/200 | 14/99 | 18/102 | 32/201 |
| Age, Customized(Participants) | Asciminib (Imatinib Stratum) | Asciminib (2nd Generation TKI Stratum) | Investigator Selected TKI (Imatinib Stratum) | Investigator Selected TKI (2nd Generation TKI Stratum) | Total |
|---|---|---|---|---|---|
| 18 to <65 years | 69 | 86 | 70 | 85 | 310 |
| 65 to <75 years | 24 | 12 | 22 | 12 | 70 |
| >= 75 years | 8 | 2 | 10 | 5 | 25 |
| Sex: Female, Male(Participants) | Asciminib (Imatinib Stratum) | Asciminib (2nd Generation TKI Stratum) | Investigator Selected TKI (Imatinib Stratum) | Investigator Selected TKI (2nd Generation TKI Stratum) | Total |
|---|---|---|---|---|---|
| Female | 39 | 31 | 37 | 42 | 149 |
| Male | 62 | 69 | 65 | 60 | 256 |
| Race/Ethnicity, Customized(Participants) | Asciminib (Imatinib Stratum) | Asciminib (2nd Generation TKI Stratum) | Investigator Selected TKI (Imatinib Stratum) | Investigator Selected TKI (2nd Generation TKI Stratum) | Total |
|---|---|---|---|---|---|
| White | 63 | 45 | 66 | 44 | 218 |
| Black or African American | 1 | 1 | 1 | 1 | 4 |
| Asian | 37 | 53 | 34 | 56 | 180 |
| Unknown | 0 | 1 | 1 | 1 | 3 |
| EUTOS Long-Term Survival (ELTS) score(Participants) | Asciminib (Imatinib Stratum) | Asciminib (2nd Generation TKI Stratum) | Investigator Selected TKI (Imatinib Stratum) | Investigator Selected TKI (2nd Generation TKI Stratum) | Total |
|---|---|---|---|---|---|
| Low | 62 | 60 | 64 | 61 | 247 |
| Intermediate | 30 | 26 | 30 | 27 | 113 |
| High | 9 | 14 | 8 | 14 | 45 |
Showing the first 100 of 110 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Oct 2021 to primary completion in Nov 2023, 25 months.
Results were first posted in Mar 2025, 1 year 3 months after primary completion.
Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asciminib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →